Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs FedEx Corporation (FDX) Price & Performance

DexCom, Inc.Trade
FedEx CorporationTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs FedEx Corporation — how do they compare? DexCom, Inc. trades at $83.92 (market cap $31.86B), while FedEx Corporation trades at $290.52 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and FedEx Corporation pays a 1.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and FedEx Corporation for 87 Days on average.

DXCMFDX
Market Cap
$31.86B$69.04B
Volume
3,607,0701,287,367
Sector
HealthIndustrials
52-Week High
$92.34$339.35
52-Week Low
$54.84$180.87
Typical Hold Time
62 Days87 Days
Enterprise Value
$31.32B$98.68B
Dividend Yield
—1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

FedEx Corporation

FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.

The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
FDX
100% Buy0% Sell
Avg holding period · 87 Days

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX →